Innovating Works

Teva Pharmaceuticals Europe B.V.

Desconocido
GLIOTRAIN: Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational... TEVA PHARMACEUTICALS EUROPE B.V. participó en un H2020: H2020-MSCA-ITN-2017 Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patien...
2017-08-29 - 2021-08-31 | Financiado
IPIE: Intelligent Assessment of Pharmaceutical in the Environment TEVA PHARMACEUTICALS EUROPE B.V. participó en un FP6: Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patie...
2015-01-01 - 2019-06-30 | Financiado
BIO-DrIM: Personalized minimization of immunosuppression after solid organ transplantation by biomarker driven... TEVA PHARMACEUTICALS EUROPE B.V. participó en un FP7: Organ transplantation has emerged as the gold standard therapy for end-stage organ failure. Incomplete control of chronic allograft injury b...
Financiado
IPIE: Intelligent Assessment of Pharmaceutical in the Environment TEVA PHARMACEUTICALS EUROPE B.V. participó en un FP7: Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patie...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.